Market Cap: $391.63M
EI
Editas Medicine, Inc.
EDIT
NASDAQUSD
Market Cap: $391.63M
Editas Medicine Leverages Gene-Editing Innovations to Expand Market Presence Editas Medicine announces its fourth-quarter earnings, revealing significant revenue growth primarily driven by the commerc…
Editas Medicine’s Commitment to Gene Editing Innovations Shines Through Q4 Results Editas Medicine announces its Q4 earnings results, marking a robust performance driven by increased commercialization…
Concentrates in Beauty Reflect Precision and Efficiency Trends Concentrated consumer formulations are emerging as a visible example of a broader efficiency push that resonates with precision biopharma…
Novel Concentration Trend Offers Lessons for Gene‑Editing Formulation The Hair Edit’s launch of ultra‑concentrated Hair Care Concentrates at Target signals a broader move across product industries tow…
Concentrated actives in cosmetics highlight parallels with precision delivery challenges in gene editing A consumer-facing move by The Hair Edit to launch ultra‑concentrated hair care at Target unders…
Concerns Over CRISPR Therapy Safety Impact Intellia Therapeutics’ Clinical Trials Intellia Therapeutics Inc. faces significant challenges following the announcement of a temporary pause in patient dos…
Patient Safety Concerns Cast Shadow on CRISPR Advancements In a notable development within the gene-editing landscape, Intellia Therapeutics Inc. faces significant challenges following a temporary hal…
Editas Medicine and the Future of Longevity Biotechnology Editas Medicine stands at the intersection of gene editing and the emerging longevity biotechnology sector, where innovative solutions to age-…
Editas Medicine Eyes the Future of Longevity Biotechnology Editas Medicine is actively positioned within the rapidly evolving landscape of longevity biotechnology, a sector that is gaining traction as…
Empowering Women Through Menopause Awareness: Nutrafol Launches 'The Menopause Edit' In a significant move to address a critical gap in midlife health discussions, Nutrafol, a leader in dermatologist-…
Editas Medicine: Navigating the Landscape of Gene Editing Editas Medicine continues to draw attention as it progresses in the field of gene editing, particularly in its mission to develop transformati…
Eli Lilly's Strategic Acquisition: A Leap into Genetic Cardiovascular Treatments Eli Lilly and Co. (LLY) recently announces its acquisition of Verve Therapeutics, Inc. (VERV), a Boston-based company t…
Eli Lilly's Strategic Acquisition: A Pivotal Move in Genetic Medicine Eli Lilly and Co’s recent acquisition of Verve Therapeutics, Inc. marks a significant stride in the realm of genetic medicine, par…
Eli Lilly's Strategic Acquisition: A New Era in Genetic Medicine for Cardiovascular Disease Eli Lilly and Co. announces its acquisition of Verve Therapeutics, Inc., a Boston-based company specializing…
Editas Medicine's Focus on Genetic Innovation Amidst Cultural Events In a rapidly evolving landscape of biotechnology, Editas Medicine continues to prioritize its mission of advancing genomic medicine…
Editas Medicine's Commitment to Mental Health: A Focus on Social Responsibility Through Fashion Editas Medicine, a pioneering company in the field of gene editing, recognizes the importance of social…